MX2018003311A - Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario. - Google Patents
Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario.Info
- Publication number
- MX2018003311A MX2018003311A MX2018003311A MX2018003311A MX2018003311A MX 2018003311 A MX2018003311 A MX 2018003311A MX 2018003311 A MX2018003311 A MX 2018003311A MX 2018003311 A MX2018003311 A MX 2018003311A MX 2018003311 A MX2018003311 A MX 2018003311A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- intermediate compound
- producing same
- guna
- crosslinked nucleic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona un método para producir ácido nucleico artificial entrelazado con guanidina (abreviado en lo sucesivo como GuNA), y un compuesto intermedio para la producción del mismo; específicamente, la presente invención proporciona un método para producir un compuesto representado por la fórmula general I: (en la fórmula, R1, R2, R3, R4, R5, R6, m y el anillo A son como se define en la especificación) o una sal del mismo en donde se hace reaccionar un agente de reducción con un compuesto representado por la fórmula general II: (en la fórmula R1, R2, R3, R4, R5, R6, m y el anillo A' son como se definen en la especificación).(ver formulas).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015185730 | 2015-09-18 | ||
| JP2016039351 | 2016-03-01 | ||
| PCT/JP2016/077748 WO2017047816A1 (ja) | 2015-09-18 | 2016-09-20 | 架橋型核酸GuNA、その製造方法および中間体化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018003311A true MX2018003311A (es) | 2019-02-07 |
Family
ID=58289462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003311A MX2018003311A (es) | 2015-09-18 | 2016-09-20 | Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10961269B2 (es) |
| EP (2) | EP3351548B1 (es) |
| JP (4) | JP6994197B2 (es) |
| KR (1) | KR20180057651A (es) |
| CN (1) | CN108137638B (es) |
| AU (1) | AU2016324126A1 (es) |
| BR (1) | BR112018005284A2 (es) |
| HK (1) | HK1251577A1 (es) |
| MX (1) | MX2018003311A (es) |
| PH (1) | PH12018500582A1 (es) |
| RU (1) | RU2018113811A (es) |
| SG (1) | SG11201802190UA (es) |
| TW (1) | TW201718618A (es) |
| WO (1) | WO2017047816A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸GuNA,其製造方法,及中間體化合物 |
| KR102131898B1 (ko) * | 2017-10-31 | 2020-07-08 | 주식회사 노벨티노빌리티 | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 |
| JP2019119739A (ja) * | 2017-12-28 | 2019-07-22 | 国立大学法人岐阜大学 | ヌクレオシド誘導体の製造方法 |
| MY208522A (en) * | 2018-11-12 | 2025-05-14 | Mitsubishi Tanabe Pharma Corp | Crosslinked artificial nucleic acid alna |
| CA3198029A1 (en) | 2019-03-29 | 2020-10-08 | Mitsubishi Tanabe Pharma Corporation | Compound, method and pharmaceutical composition for modulating expression of dux4 |
| CN115667513A (zh) | 2020-05-12 | 2023-01-31 | 田边三菱制药株式会社 | 用于调节Ataxin 3表达的化合物、方法和药物组合物 |
| JP2023130528A (ja) * | 2020-06-24 | 2023-09-21 | 田辺三菱製薬株式会社 | Plp1発現を調節するための化合物、方法及び医薬組成物 |
| JP2024105742A (ja) * | 2021-05-26 | 2024-08-07 | ルクサナバイオテク株式会社 | 心疾患治療薬 |
| WO2023177808A1 (en) * | 2022-03-17 | 2023-09-21 | Aligos Therapeutics, Inc. | Modified gapmer oligomers and methods of use thereof |
| WO2024101446A1 (ja) * | 2022-11-10 | 2024-05-16 | ルクサナバイオテク株式会社 | 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法 |
| WO2024135721A1 (ja) | 2022-12-21 | 2024-06-27 | 田辺三菱製薬株式会社 | 製造中間体の製造方法、その製造中間体及びそれらを用いた架橋型人工核酸中間体の製造方法 |
| WO2025206092A1 (ja) * | 2024-03-27 | 2025-10-02 | 田辺三菱製薬株式会社 | Myoregulin発現を調節するための化合物及び医薬組成物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09328497A (ja) | 1996-04-12 | 1997-12-22 | Yamasa Shoyu Co Ltd | 4’−フルオロメチルヌクレオシド |
| JP3756313B2 (ja) * | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| DE69829760T3 (de) * | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6794499B2 (en) * | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| ES2431586T3 (es) | 2002-02-13 | 2013-11-27 | Takeshi Imanishi | Análogos de nucleósidos y derivado de oligonucleótido que comprende un análogo de nucleótido del mismo |
| WO2003095467A1 (en) | 2002-05-08 | 2003-11-20 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| DK1661905T3 (da) * | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| WO2007145593A1 (en) | 2006-06-15 | 2007-12-21 | Jyoti Chattopadhyaya | Conformationally constrained 2' -n,4' -c-ethylene-bridged thymidine (aza-ena-t) |
| US20100062994A1 (en) * | 2006-07-14 | 2010-03-11 | Santaris Pharma A/S | Adenosine Receptor Antagonists |
| AU2010312751B2 (en) * | 2009-10-29 | 2014-07-24 | Osaka University | Bridged artificial nucleoside and nucleotide |
| WO2011156202A1 (en) * | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| CA2842103A1 (en) * | 2011-07-19 | 2013-01-24 | University Of Idaho | Embodiments of a probe and method for targeting nucleic acids |
| US10377789B2 (en) * | 2012-09-21 | 2019-08-13 | Osaka University | Oligonucleotide and artificial nucleoside having guanidine bridge |
| EP2909222B1 (en) * | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
| JP6270742B2 (ja) * | 2013-01-10 | 2018-01-31 | 塩野義製薬株式会社 | 架橋型核酸誘導体の製造方法 |
| WO2014124952A1 (en) | 2013-02-12 | 2014-08-21 | Syddansk Universitet | "clickable" alkyne-lna oligonucleotides |
| SG10201804835VA (en) | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| WO2016145142A1 (en) * | 2015-03-10 | 2016-09-15 | Emory University | Nucleotide and nucleoside therapeutics compositions and uses related thereto |
| TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸GuNA,其製造方法,及中間體化合物 |
-
2016
- 2016-09-19 TW TW105130154A patent/TW201718618A/zh unknown
- 2016-09-20 SG SG11201802190UA patent/SG11201802190UA/en unknown
- 2016-09-20 EP EP16846687.8A patent/EP3351548B1/en active Active
- 2016-09-20 RU RU2018113811A patent/RU2018113811A/ru not_active Application Discontinuation
- 2016-09-20 WO PCT/JP2016/077748 patent/WO2017047816A1/ja not_active Ceased
- 2016-09-20 HK HK18110863.3A patent/HK1251577A1/en unknown
- 2016-09-20 MX MX2018003311A patent/MX2018003311A/es unknown
- 2016-09-20 JP JP2017540049A patent/JP6994197B2/ja active Active
- 2016-09-20 US US15/760,513 patent/US10961269B2/en active Active
- 2016-09-20 KR KR1020187010564A patent/KR20180057651A/ko not_active Withdrawn
- 2016-09-20 CN CN201680054199.3A patent/CN108137638B/zh active Active
- 2016-09-20 EP EP21190084.0A patent/EP3974436A1/en active Pending
- 2016-09-20 BR BR112018005284-1A patent/BR112018005284A2/pt not_active Application Discontinuation
- 2016-09-20 AU AU2016324126A patent/AU2016324126A1/en not_active Abandoned
-
2018
- 2018-03-16 PH PH12018500582A patent/PH12018500582A1/en unknown
-
2021
- 2021-12-01 JP JP2021195554A patent/JP2022033869A/ja active Pending
-
2023
- 2023-03-16 JP JP2023041934A patent/JP2023075302A/ja active Pending
-
2024
- 2024-07-31 JP JP2024124561A patent/JP2024153835A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3351548B1 (en) | 2025-08-20 |
| EP3351548A4 (en) | 2019-06-12 |
| EP3974436A1 (en) | 2022-03-30 |
| EP3351548A1 (en) | 2018-07-25 |
| KR20180057651A (ko) | 2018-05-30 |
| CN108137638B (zh) | 2022-05-03 |
| AU2016324126A1 (en) | 2018-05-10 |
| BR112018005284A2 (pt) | 2018-12-11 |
| PH12018500582A1 (en) | 2018-09-10 |
| TW201718618A (zh) | 2017-06-01 |
| HK1251577A1 (en) | 2019-02-01 |
| JP2022033869A (ja) | 2022-03-02 |
| JP2023075302A (ja) | 2023-05-30 |
| RU2018113811A (ru) | 2019-10-18 |
| CN108137638A (zh) | 2018-06-08 |
| JP6994197B2 (ja) | 2022-01-14 |
| US10961269B2 (en) | 2021-03-30 |
| JP2024153835A (ja) | 2024-10-29 |
| SG11201802190UA (en) | 2018-04-27 |
| JPWO2017047816A1 (ja) | 2018-07-05 |
| WO2017047816A1 (ja) | 2017-03-23 |
| US20180251488A1 (en) | 2018-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003311A (es) | Ácido nucleico artificial puenteado a guanidina, entrelazado, método para la producción del mismo, y compuesto intermediario. | |
| DOP2022000172A (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) | |
| MX2019012815A (es) | Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo. | |
| CL2017003404A1 (es) | Compuestos antibacterianos | |
| MX373436B (es) | Compuesto peptidico. | |
| MX2021016054A (es) | Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales. | |
| CL2018000786A1 (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| EA029568B8 (ru) | Бигетероарильные соединения и их применения | |
| CU24408B1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
| UY37932A (es) | Proceso para producir compuestos de piridazinona herbicidas | |
| UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| MA38982A1 (fr) | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl | |
| MY194307A (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| CL2017001100A1 (es) | Nuevas triazolo[4,5-d]pirimidinas | |
| MX2019005254A (es) | Proceso para la purificacion de pirazolpiridazinas. | |
| ECSP20080995A (es) | Derivados de tetrahidrotienopiridina nsustituidos y sus usos | |
| MX2018008966A (es) | Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo. | |
| MX382702B (es) | Nuevos compuestos de sulfonilaminobenzamida como antihelminticos. | |
| CR20150594A (es) | N-(2-fluoro-2-fenetil)carboxamidas como nematicidas y endoparasiticidas | |
| MX2020003922A (es) | Proceso para producir compuestos de piridazinona herbicida. | |
| UY37211A (es) | Proceso para la preparacion de piridinilimidazolonas | |
| UY37210A (es) | Proceso para la preparación de piridinilimidazolonas | |
| RU2013113468A (ru) | 2-({[(1s,2r,5s)-6,6-диметилбицикло[3.1.1]гепт-2-ил]метил}сульфинил)этановая кислота, обладающая антиагрегационным действием | |
| MX2016005220A (es) | Tinturas acidas, proceso para su produccion y su uso. |